The TAONas-LUAD project focuses on developing an application of antisense oligonucleotides (AON)-based splicing modulation in clinical oncology.
Alterations in alternative splicing (AS), a process leading to the synthesis of different protein variants from a single gene, contribute to all cancer hallmarks. Splicing modulation therapies based on the use of AONs have revolutionized treating many other diseases but haven’t yet been successfully applied to cancer.

Our proprietary AONs prevent lung cancer cell proliferation in vitro and inhibit tumor growth in mouse models of human Lung Adenocarcinoma (LUAD), showing promising results for developing improved treatments.